EBV specific CTL: a model for immune therapy

Vox Sang. 1998;74 Suppl 2:497-8. doi: 10.1111/j.1423-0410.1998.tb05463.x.


We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.

Publication types

  • Review

MeSH terms

  • Bone Marrow Transplantation / adverse effects
  • Cell Survival
  • Epstein-Barr Virus Infections / immunology
  • Epstein-Barr Virus Infections / pathology
  • Epstein-Barr Virus Infections / therapy*
  • Epstein-Barr Virus Infections / virology
  • Genetic Markers
  • Genetic Vectors / analysis
  • Herpesvirus 4, Human / immunology*
  • Humans
  • Immunotherapy, Adoptive*
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / immunology
  • Lymphoproliferative Disorders / prevention & control*
  • Lymphoproliferative Disorders / therapy
  • Lymphoproliferative Disorders / virology
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Cytotoxic / transplantation
  • Time Factors
  • Treatment Outcome


  • Genetic Markers